Form PTO-1396-MOD U. S. Department of Commierce Flatent and Trademark Office (REV 10-96)	ATTORNEY'S DOCKET NUMBER 33639-US-PCT							
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371	U.S. APPLICATION NO. (19 known, see 37 CFR 1.5) 10/564,698							
INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PCT/EP04/07842 July 15, 2004	PRIORITY DATE CLAIMED 15 July 2003 (15.07.03)							
TITLE OF INVENTION SECRETED POLUPEPTIDE SPECIES REDUCED IN CARDIOVASCULAR DISC	ORDERS							
APPLICANT(S) FOR DO/EO/US Guilaine Argoud-Puy								
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the	na following items and other information:							
 This is a FIRST submission of items concerning a filling under 35 U.S.C. 371. ∑ This is a SECOND or SUBSEQUENT submission of items concerning a filling under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. A copy of the International Application as filled (35 U.S.C. 371(c)(2)) 								
a. is transmitted herewith (required only if not transmitted by the International Bureau). b. has been transmitted by the International Bureau. (See Form PCT/IB/308) c. is not required, as the application was filed in the United States Receiving Office (RO/US) A translation of the International Application into English (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)). a. are transmitted herewith (required only if not transmitted by the International Bureau). b. have been transmitted by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired.								
d. [] have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).								
Items 11. to 16. below concern document(s) or information included.								
11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.								
12. An assignment document for recording. A separate cover sheet in compliance w	ith 37 CFR 3.28 and 3.31 is included.							
A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.								
14. An Application Data Sheet under 37 CFR 1.76.								
15. A substitute specification.								
16. A change of power of attorney and/or address letter.								
17. A computer-readable form of the sequence listing in accordance with PCT Rule 1	3ter.2 and 37 CFR 1:821-1.825.							
18. A second copy of the published international Application under 35 U.S.C. 154(d)(4).							
19. A second copy of the English language translation of the International application	under 35 U.S.C. 154(d)(4).							

20. \square Other items or information:

	(if known, see 37 CFR 1.5		INTERNATIONAL APPLICATION N	io.				XOCKET NUMBER			
10/564,698	/564,698 PCT/EP84/87842 33639-US			639~US							
The following fees are submitted:							CALCULATIONS PTO USE				
21. Basic	21. Basic national feet the state of the sta										
22. Examination Fee											
if inte	emational prelimin		ation report was prepare								
and all claims satisfy provisions of PCT Article 33(1)-(4)											
All other situations.											
23. Search fee											
If Search fee (37 CFR 1.445(a)(2)) has been paid on the international											
			emational Searching Au			\$ \$	8				
			prepared and provided	ia ine Ui	nce.	\$					
All other situations\$											
		TOTAL	_ OF 21, 22 AND 23 =					\$	0		
			led in paper over 100 sh								
program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.											
Total Sheets	Extra sheets		of each additional 50 or		T	RATE				•••••	
- 100 =	/50 ≈		ound up to a whole num	iber)	X	\$	250	S			
- 100 = 1	1 /50 =		·····		<u></u>	<u> </u>	ಪರಿಟ	3			
				⊠ 30				s			
			(37 CFR 1,492(e)).								
CLAIMS	NUM	BER FILED			~~~~~~	RATE	EO:				
Total claims		- 20	^^^^^		X \$ X \$:	50	\$			
					S						
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360 TOTAL OF ABOVE CALCULATIONS =						S	8				
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be											
filed (Note 37 CFR 1.9, 1.27, 1.28).					\$						
SUBTOTAL =						S					
Processing fee of \$130 for furnishing the English translation later than 🔲 30 months from the											
earliest claimed priority date (37 CFR 1.492(f)). +						\$					
			***************************************	~~~~~~~~~	NATIC			S		****	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +						\$					
TOTAL FEES ENCLOSED =						\$					
101AL1 LEO LITOCOSCO -							Amount		œ		
							be: refund		4.		
							charg		\$		
a. A check in the amount of \$ to cover the above fees is enclosed.											
b. Please charge Deposit Account No. 50-4409 in the name of Novartis in the amount of \$ to cover the above fees. A duplicate copy of this form is enclosed.											
					Section 1						
 The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-4409 in the name of Novartis. 											
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.											
Send all correspondence to the address associated with											
Send all correspondence to the address associated with Customer No. 75075, which is currently: Paul J. Packerani											
<u>.</u>	المنت عمال المراجع الوالد	. سدد در بو				17.25	A. C.			-	
Novartis Institutes for BioMedical Research, Inc. Attorney for Applicant 400 Technology Square Reg. No. 52,498											
400 Technology Square Reg. No. 52/498 Cambridge, MA 02139 (617) 871-3343											
Commission of European Commission and Commission an											